DelveInsight’s “Advanced Pancreatic Cancer Pipeline Perspective, 2021” report provides in-depth analysis of the Advanced Pancreatic Cancer market’s current clinical development landscape and growth prospects. The disease summary and Advanced Pancreatic Cancer care recommendations are included in a clear image of the Advanced Pancreatic Cancer pipeline landscape along with a detailed layout of pipeline therapies in different stages, with different MoA, RoA, Product type, Molecule type, and so on.
Some of the Crucial Highlights from the Advanced Pancreatic Cancer Pipeline Report
There are more than 60 Advanced Pancreatic Cancer pipeline therapies in various stages of production, and their projected entry in the Advanced Pancreatic Cancer market will result in substantial market revenue growth.
For Advanced Pancreatic Cancer, emerging therapies like Eryaspase, EndoTAG-1, and Masitinib are in Phase III clinical trials, while IMM-101, Anktiva, and CAN-2409 are in Phase II trials.
Some pipeline therapies, such as L-DOS 47, are in the Phase I/II of clinical development for Advanced Pancreatic Cancer.
To know more request sample @ Advanced Pancreatic Cancer Pipeline Insights
Advanced Pancreatic Cancer: Disease Overview
When Pancreatic Cancer is unresectable or cannot be removed by surgery, it is considered advanced. The cancer has spread to adjacent blood vessels or lymph nodes, as well as organs beyond the pancreas (metastasis). In most cases, this is step III or IV. There are two types of stage IV pancreatic cancer- Stage IVA and Stage IVB.
Advanced Pancreatic Cancer: Symptoms
Pancreatic cancer may cause only vague, unexplained symptoms, such as abdominal or back pain, weight loss, and nausea. Jaundice (yellowing of the skin, eyes, or both) with or without scratching is a condition in which the skin, eyes, or both are yellow. Appetite loss, and nauseous, a change in stool Recent-onset diabetes, pancreatitis
Advanced Pancreatic Cancer: Treatment
Pancreatic cancer is often not detected until it has progressed to Stage IVA, which means the cancer has spread to other organs or large blood vessels. Surgical removal of the cancer (which offers a possibility of long-term cure) is rarely an option when this happens. As a result, the aim of treatment for Stage IVA pancreatic cancer patients is to promote remission, which is a cancer-free duration that can last months or years, as well as to avoid and monitor symptoms.
To gain more insights visit Advanced Pancreatic Cancer Treatment Landscape
Advanced Pancreatic Cancer Pipeline Analysis: Drug Profile
EndoTAG-1: Syncore Biotechnology
EndoTAG-1 (SB05) is a novel combination of paclitaxel, a well-known cytostatic compound, and neutral and positive lipids. SB05 interacts with newly developing, negatively charged endothelial cells, which are particularly important for the growth of tumour blood vessels, due to the positively charged lipids. The SB05 paclitaxel portion targets activated endothelial cells as they divide, limiting blood flow to tumours while not affecting healthy tissue’s non-activated endothelial cells. SB05 is supposed to stop the development of new tumour blood vessels and slow tumour growth by doing so.
Research and Development in the Advanced Pancreatic Cancer Pipeline Landscape
NCT03126435: SynCore Biotechnology began a randomised controlled, open label, adaptive phase-3 trial in June 2018 to compare the safety and efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in patients with detectable locally advanced and/or metastatic adenocarcinoma of the pancreas who had failed FOLFIRINOX therapy. By June 2022, the trial is expected to be completed.
Advanced Pancreatic Cancer Pipeline Therapies and Key Companies
Eryaspase: ERYtech Pharma
EndoTAG-1: Syncore Biotechnology
Masitinib: AB Science
IMM-101 : Immodulon Therapeutics
CAN-2409: Candel Therapeutics
L-DOS 47: Helix BioPharma
Advanced Pancreatic Cancer Therapeutics Assessment
By Product Type
By Route of Administration
By Molecule Type
Stem Cell Therapy
By Mechanism of Action
Scope of the Report
Advanced Pancreatic Cancer Key Players: ERYtech Pharma, Syncore Biotechnology, AB Science, Immodulon Therapeutics, ImmunityBio, Candel Therapeutics, Helix BioPharma, among others.
Advanced Pancreatic Cancer Pipeline Therapies: Eryaspase, EndoTAG-1, Masitinib, IMM-101, Anktiva, CAN-2409, L-DOS 47, and others.
Table of Contents
Advanced Pancreatic Cancer: Overview
Advanced Pancreatic Cancer- Analytical Perspective In-depth Commercial Assessment
Advanced Pancreatic Cancer: Pipeline Therapeutics
Advanced Pancreatic Cancer: Late Stage Products (Phase III)
Advanced Pancreatic Cancer: Mid Stage Products (Phase II)
Advanced Pancreatic Cancer: Early Stage Products (Phase I/II)
Advanced Pancreatic Cancer: Preclinical Stage Products
Advanced Pancreatic Cancer: Therapeutic Assessment
Advanced Pancreatic Cancer: Inactive Products
Advanced Pancreatic Cancer: Company-University Collaborations (Licensing/Partnering) Analysis
Advanced Pancreatic Cancer Key Companies
Advanced Pancreatic Cancer Key Products
Advanced Pancreatic Cancer- Unmet Needs
Advanced Pancreatic Cancer- Market Drivers and Barriers
Advanced Pancreatic Cancer- Future Perspectives and Conclusion
Advanced Pancreatic Cancer Analyst Views
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Key Questions Answered in the Advanced Pancreatic Cancer Report
What are the treatment choices for Advanced Pancreatic Cancer that has progressed?
How many companies are developing Advanced Pancreatic Cancer treatments?
What are the most popular therapies produced by these companies in the industry?
How many Advanced Pancreatic Cancer therapies are being produced by each company?
How many emerging Advanced Pancreatic Cancer therapies are being developed for the treatment of Advanced Pancreatic Cancer in its early, middle, and late stages?
Out of the total pipeline drugs, how many are provided as monotherapies and in combination with other therapies?
What are the most important industry-industry and industry-academia collaborations, mergers and acquisitions, and significant licencing activities that will impact Advanced Pancreatic Cancer?
Advanced Cancer Pain Management Market
Get comprehensive historical and forecast analysis of Advanced Cancer Pain Management (ACPM) Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Medlab, Pfizer, Sorrento Therapeutics, Inc., Tetra Bio-Pharma, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States